Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection

Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.

Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.

Patients will be asked to document their orolabial lesions with photos by using their smart phone

Patients will be asked to document their health status in questionnaires by using their smart phone

Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions

Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.